Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...
Recursion recently advanced REC-1245 into clinical trials, a drug candidate developed using the company's end-to-end workflow. Results from this program will be more meaningful, although trial results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results